) ... GCWL/Corp/PSX-28 ... Disclosure of Interest by a DirectorCEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.4.(d) of PSX Regulations ... Sr. No ... 5.6.1.(d) of PSX Regulations and confirm the same to the Exchange.
Disclosure of Interest bY a Director under clause 5.6.4 of PSX Requlations Dear Sir,. In compliance with clause 5.6.4 of the RuleBook of PSX, we hereby inform you that Mrs.
Expands clinical expertise to support disciplined advancement of the PSX-001 program ... Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder.